维普期刊资源整合服务平台（V6.5）

48篇 您的检索式：作者名="VALKEMA R"

选中清除导出查看参考文献查看引证文献引用追踪共3页首页上一页第1页下一页末页 /3 跳转

	题名	作者	年代	出处	被引量
1	Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: relevence of kidney volume and dose rate in finding a dose-effect relationship 显示文摘	Barone R Borson-Chazot F Valkema R	2005	J Nucl Med2005，，：	1
2	Survival and response after peptide receptor radionuelide therapy with octreotide in patients with advanced gastroenteropancreatie neuroendocrine tumors显示文摘	Valkema R Pauwels S Kvols LK	2006	Semin Nucl Med2006，36，2：	1
3	Bone mineral density in ambulant, non-steroid treated female patients with rheumatoid arthritis显示文摘	Eggelmeijer F Camps JA Valkema R	1993	Clin Exp Rheumatol1993，11，：	1
4	Single-photon emission computed tomography for assessment of myocardial viability 显示文摘	Schinkel AF Valkema R Geleijnse ML	2010	Eu- roIntervention2010，6，：	1
5	Nuclear medicine techniques for the imaging and treatment of neu- roendocrine tumours显示文摘	Teunissen JJ Kwekkeboom D J Valkema R	2011	Endocr Relat Cancer2011，18，1：	1
6	Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine显示文摘	Rolleman EJ Valkema R de Jong M	2003	Eur J Nucl Med Mol Imaging2003，30，1：	1
7	Combination radionuclide therapy using ^177Lu-and 90Y-Labeled somatostatin analogs显示文摘	JONG M BREEMAN WAP VALKEMA R	2005	J Nucl Med2005，46，1：	1
8	Soma- radionuclide therapy oftumors: preclinical and clinical findings显示文摘	De Jong M Valkema R tostatin receptor-targeted Jamar F	2002	Semin Nucl Med2002，32，2：	1
9	The role of radioactive somatostatin and its analogues in the control oftumor growth显示文摘	Krenning EP Valkema R Kooij PP	2000	Recent Results Cancer Res2000，153，：	1
10	Molecular radiotherapy with somatostatin analogs for (neuro-) endocrine tumors显示文摘	Krenning EP Teunissen JJ Valkema R	2005	J Endocrinol Invest2005，28，11：	1
11	Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate 显示文摘	Valkema R Pauwels SA Kvols LK	2005	J Nucl Med2005，46，1：	1
12	Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability显示文摘	SCHINKEL A F BAX J J VALKEMA R	2003	J Nucl Med2003，44，6：	1
13	Feasibility and image quality of dual-isotope SPECT using 18F-FDG and (99m)Tc-tetrofosmin after acipimox administration显示文摘	KAM B L VALKEMA R POLDERMANS D	2003	J Nucl Med2003，44，2：	1
14	Neuroendocrine tumors and somatostatin: imaging techniques 显示文摘	de HERDER WW KWEKKEBOOM D J VALKEMA R el al	2005	J Endocrinol Invest2005，28，11：	1
15	Combination radionuelide therapy using 177Lu- and 90Y-labeled somatostatin analogs显示文摘	de Jong M Breeman WA Valkema R	2005	J Nucl Med2005，46，1：	1
16	Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas显示文摘	Lugtenburg PJ Lowenberg B Valkema R	2001	J Nucl Med2001，42，：	1
17	Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: More extended disease identified显示文摘	Lugtenburg PJ Krenning EP Valkema R	2001	Br J Hematol2001，112，4：	1
18	Single-photon e- mission computed tomography for assessment of myocardial via- bility显示文摘	Schinkel AF Valkema R Geleijnse ML	2010	Eur Interv2010，6，：	1
19	The Role of Radioactive Somatostatin and Its Analogues in the Control of Tumor Growth显示文摘	Krenning EP Valkema R Kooij P	2000	Recent Results Cancer Res2000，153，：	1
20	P-hase I Study of Peptide Receptor Radionuclide Therapy Withoctreotide: the Rotterdam Experience显示文摘	Valkema R De Jong M Bakker WH	2002	Semin Nucl Med2002，32，2：	1

返回顶部每页显示：

共3页首页上一页第1页下一页末页 /3 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示